贪婪
受体
加强
抗体
免疫疗法
封锁
T细胞
化学
细胞
癌症研究
癌症免疫疗法
共刺激
细胞生物学
免疫学
细胞毒性
计算生物学
细胞表面受体
医学
CD8型
提吉特
T细胞受体
作者
Marcus A. Widdess,Anastasia Pakidi,Hannah J. Metcalfe,H. T. Claude Chan,Tatyana Inzhelevskaya,Chris Penfold,Christopher Ian Mockridge,Steven G. Booth,Sonya James,Sean H. Lim,Stephen A. Beers,Mark Steven Cragg,Aymen Al‐Shamkhani
标识
DOI:10.1038/s41467-025-67882-3
摘要
Despite significant clinical progress, checkpoint blockade remains limited by variable response rates, resistance, and toxicity. Activating costimulatory receptors offers a promising alternative to enhance anti-tumor immunity. However, there is insufficient understanding of how to mimic physiological membrane-anchored costimulatory ligands. Here, we describe a strategy for developing effective agonists of the costimulatory receptor CD27 by increasing both antibody valency and FcγRIIB engagement. Engineered anti-CD27 antibodies capable of tetravalent binding to CD27 and selective FcγRIIB association exhibit potent T cell stimulatory activity and anti-tumor efficacy in pre-clinical models, compared to bivalent counterparts. The anti-tumor effects of the tetravalent antibody are mediated through CD8⁺ T cell activation without evidence of regulatory T cell depletion. Mechanistically, whereas the increase in avidity drives more efficient CD27 clustering, FcγRIIB engagement triggers polarization of receptor clusters to the cell-cell interface and reduces receptor internalization. This work provides a framework for developing more effective agonist-based T cell stimulatory therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI